The comparative analysis of TNF-antagonist monotherapy, combination therapy (adjusted OR 4.01, 95% CI 1.65–9.78), and thiopurine monotherapy (adjusted OR 4.08, 95% CI 1.73–9.61) showed a significantly increased risk of severe COVID-19 [54]. The gene discussed is TNF; the disease is COVID-19.